single5MG
CJC-1295 DAC
5MG Protocol
CJC-1295 DAC 5MG
Injection Freq.
Inject twice weekly
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
2.0 mL BAC water
Sustained elevation of GH and IGF-1 in a dose-dependent manner
Potential support for lean mass and reduced fat mass via GH/IGF-1 axis signaling
Enhanced protein-synthesis and recovery signaling (as described)
Generally well tolerated in referenced studies
1
Reconstitution Requirements
- 2.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 300 mcg (0.3 mg) | 12 |
| 2 | Weeks 3–4 | 500 mcg (0.5 mg) | 20 |
| 3 | Weeks 5–6 | 750 mcg (0.75 mg) | 30 |
| 4 | Weeks 7–12 | 1000 mcg (1 mg) | 40 |
Inject twice weekly
8–12 weeks; optional extension to 16 weeks
CJC-1295 DAC is described as a long-acting analog of growth hormone–releasing hormone (GHRH). The protocol explains that the DAC (Drug Affinity Complex) modification enables reversible albumin binding, extending the peptide’s half-life to multiple days compared with minutes for typical GHRH analogs. Mechanistically, it binds GHRH receptors on pituitary somatotrophs and drives growth hormone release, which then raises IGF-1 (primarily hepatic) as a downstream mediator of many growth and metabolic effects. Importantly, the page notes that GH secretion remains pulsatile even with continuous stimulation, suggesting preservation of physiologic release patterns. The overall rationale presented is sustained GH/IGF-1 axis activation with less frequent dosing. The protocol frames potential outcomes in terms of body-composition shifts and recovery/anabolic signaling, while noting that tolerability issues are usually mild (e.g., injection-site reactions) with some users describing transient flushing, headache, or water retention—especially during titration.
Injection-site reactions (redness/swelling)
Transient flushing
Headache
Water retention (especially during initial titration)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)